Completed PHASE2 INTERVENTIONAL 2-arm NCT00031889

Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer

A Randomized Phase II Trial of Exemestane With and Without Bicalutamide as Second Line Therapy After Failure of Androgen Suppression in Advanced Prostate Cancer

Sponsor: Swiss Cancer Institute

Conditions Prostate Cancer

Interventions Exemestane Exemestane+bicalutamide

Updated 6 times since 2017 Last updated: May 14, 2012 Started: Aug 31, 2001 Primary completion: Jun 30, 2002 Completion: Jun 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00031889, this PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by Swiss Cancer Institute, it has been updated 6 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Aug 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Aug 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Swiss Cancer Institute

Data source: Swiss Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland , Basel, Switzerland , Bern, Switzerland , Biel, Switzerland , Bruderholz, Switzerland , Chur, Switzerland , Genolier, Switzerland , Lausanne, Switzerland , Lugano, Switzerland , Mendrisio, Switzerland and 2 more locations